Cheng Shuo Wang

US Patent:

20200216860, Jul 9, 2020

Filed:

Sep 5, 2018

Appl. No.:

16/644411

Inventors:

- Tarrytown NY, US
Andrew J. MURPHY - Croton-on-Hudson NY, US
Cheng WANG - White Plains NY, US

Assignee:

Regeneron Pharmaceuticals, Inc. - Tarrytown NY

International Classification:

C12N 15/86
C12N 9/22

Abstract:

The invention provides a recombinant RNA molecule comprising (i) a sequence of a gene-editing molecule mRNA, or a sequence of a functional fragment or derivative thereof, and (ii) at least one sequence of a coding or non-coding enrichment RNA, or a sequence of a functional fragment or derivative thereof, wherein the enrichment RNA, or functional fragment or derivative thereof, is capable of enhancing inclusion of the gene-editing molecule mRNA, or functional fragment or derivative thereof, into a retroviral particle. The invention provides a method of producing the retroviral particles of the invention, the method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of retroviral particles.

US Patent:

20200154684, May 21, 2020

Filed:

Jun 27, 2018

Appl. No.:

16/625168

Inventors:

- Tarrytown NY, US
Viktoria Gusarova - Pleasantville NY, US
Cheng Wang - White Plains NY, US
Christos Kyratsous - Irvington NY, US
Terra Potocky - Dobbs Ferry NY, US
Katherine Cygnar - New York NY, US
Joel Martin - Putnam Valley NY, US

International Classification:

A01K 67/027
A61K 49/00
C07K 14/705

Abstract:

Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.

US Patent:

20200140491, May 7, 2020

Filed:

Jun 27, 2018

Appl. No.:

16/625189

Inventors:

- Tarrytown NY, US
Andrew J. Murphy - Croton-on-Hudson NY, US
Cheng Wang - White Plains NY, US
Leah Sabin - Goldens Bridge NY, US

International Classification:

C07K 14/005
C12N 7/00
C07K 16/08
C12N 15/63

Abstract:

Provided herein are compositions and methods for retargeting recombinant viral capsid proteins/capsids/vectors, e.g., in vivo, with a multispecific binding molecule, such as a bispecific antibody, that specifically binds a heterologous epitope displayed by the capsid protein and a protein expressed on the cell of interest for the targeted delivery of a nucleotide of interest.